摘要
目的:探讨急性心肌梗死(AMI)患者经皮冠状动脉介入治疗(PCI)术后口服通心络胶囊对左心功能、中医证候、生活质量、氨基末端脑钠肽前体(NT-proBNP)及炎性因子的影响。方法:将60例急性心肌梗死PCI术后患者随机按数字法,分为对照组和观察组各30例。对照组服用拜阿司匹林100 mg/次,1次/d,单硝酸异山梨酯缓释片,30 mg/次,1次/d,硫酸氢氯吡格雷片,75 mg/次,1次/d,阿托伐他汀钙片20 mg/次,1次/d,口服。观察组在对照组治疗的基础上加服通心络胶囊,4粒/次,3次/d,口服。两组疗程均为3个月。监测左心室功能,检测血清肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)水平及超敏C反应蛋白(hs-CRP)与NT-proBNP水平,记录气虚血瘀证及西雅图心绞痛量表(SAQ)评分,记录6个月内主要不良心脏事件发生情况。结果:观察组左室舒张末内径(LVEDD)、左室收缩末内径(LVESD),并测算左室射血分数(LVEF)及每搏输出量(SV)的改善均优于对照组(P<0.05或P<0.01);观察组血清NT-proBNP,TNF-α,IL-6及hs-CRP水平均低于对照组(P<0.01);观察组气虚血瘀证评分低于对照组(P<0.01);观察组SAQ评分高于对照组(P<0.01);观察组主要不良心脏事件累积发生率为13.3%,低于对照组的30.0%(P<0.01)。结论:通心络胶囊改善了急性心肌梗死PCI术后患者的心功能和心室重构,减轻了临床症状,提高了生活质量,降低了不良心脏事件的发生率。
Objective： The purpose is to study the left heart function, traditional Chinese medicine syndrome, the quality of life, amino-terminal fragment of pro-bnp（NT-proBNP） and the influence of inflammatory cytokines of the acute myocardial infarction （AMI） patients after（PCI） postoperative that took Tongxinluo capsules. Method： Sixty cases of patients with acute myocardial infarction after PCI were randomly divided into control group （30 cases） and observation group （30 cases）. Patients in the control group took aspirin, 100 mg/time, 1 time/day, orally;Isosorbide mononitrate sustained-release tablets, 30 mg/time, 1 time/day, orally;Clopidogrel 75 mg/time, 1 time/day, orally;Atorvastatin calcium 20 mg/time, 1 time/day, orally. Based on the control group, patients in the observation group additionally took Tongxinluo capsules, 4 capsules/time, 3 times/day. The treatment lasted for 3 months. The levels of left ventricular function, the detection of serum tumor necrosis factor-α （TNF-α）, interleukin 6 （IL-6）, hypersensitive c-reactive protein level （hs-CRP） and the NT-proBNP were monitored. The pneuma deficiency and blood stasis and Seattle angina questionnaire （SAQ） score were recorded, as well as the major adverse cardiac events happening within 6 months. Result： The improvements left ventricular end-diastolic diameter （LVEDD）, left ventricular contraction at the end of the inner diameter （LVESD）, left ventricular ejection fraction （LVEF） and the stroke volume （SV） of observation group are all better than those of control group （P〈0.05 or P〈0.01）. The levels of serum NT-proBNP, TNF-α, IL-6 and hs-CRP of observation group are lower than the control group （P〈0.01）. The score of pneuma deficiency and blood stasis of observation group is lower than the control group （P〈0.01）, while the SAQ score of observation group is higher than that of control group （P〈0.01）. The cumulative incidence of the major adverse cardiac events of observation group is 13.3%, which is lower than 30.0% of the control group （P〈0.01）. Conclusion： Tongxinluo capsule can improve the cardiac function and ventricular remodeling of patients with acute myocardial infarction after PCI, relieve the clinical symptoms, improve the quality of life and reduce the incidence of adverse cardiac events. Patients can benefit from multiple aspects so that it is worthy of clinical use.
出处
《中国实验方剂学杂志》
CAS
北大核心
2014年第2期196-200,共5页
Chinese Journal of Experimental Traditional Medical Formulae
基金
山东省自然科学基金项目(ZR2009CL027)
山东大学科技局科技明星计划基金项目(20100118)
山东省医学科学院医学基金项目(201023)
关键词
急性心肌梗死
经皮冠状动脉介入治疗术
通心络胶囊
acute myocardial infarction
percutaneous coronary intervention
Tongxinluo capsule
clinical benefit
